Article

In vitro testing of daptomycin plus rifampin against methicillin-resistant Staphylococcus aureus resistant to rifampin.

Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan, and formerly of Tulane Health Sciences Center, New Orleans, Louisiana, United States of America.
Saudi medical journal (impact factor: 0.52). 01/2009; 29(12):1726-9. pp.1726-9
Source: PubMed

ABSTRACT To test for synergy between daptomycin (DAP) and rifampin (RIF) against RIF-resistant methicillin-resistant Staphylococcus aureus (MRSA) isolates.
Synergy testing using time-kill assay (TKA) was performed on 6 clinically, and genetically unique RIF-resistant MRSA isolates. The isolates were identified out of 489 (1.2%) samples collected during April 2003 to August 2006, from patients at the Ochsner Medical Center in New Orleans, Louisiana, United States of America.
Synergy testing of DAP plus RIF by TKA showed that 5 isolates were indifferent, but one isolate was antagonistic.
Our in vitro study failed to demonstrate synergy between DAP plus RIF, against our RIF-resistant MRSA isolates. Clinical failure of this combination should prompt the clinician to consider antagonism, as one of the potential causes.

0 0
 · 
0 Bookmarks
 · 
25 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

6 clinically
 
antagonism
 
Clinical failure
 
genetically unique RIF-resistant MRSA
 
New Orleans
 
Ochsner Medical Center
 
patients
 
potential causes
 
RIF-resistant methicillin-resistant Staphylococcus aureus
 
RIF-resistant MRSA
 
rifampin
 
synergy
 
Synergy testing
 
time-kill assay
 
vitro study
 

Faisal A Khasawneh